KyungDong Pharm home
Prescription Medicines

Ripigrel SR Tab.

Product Category
Cardiovascular Medicines
Active Ingredients
Sarpogrelate hydrochloride
Appearance
A white, oblong, film-coated tablet.
Reimbursement Code
665507440
View Regulatory Information on the MFDS Portal ↗
1. Composition and Strength
1 tablet
- Active ingredients:
(Immediate release) Sarpogrelate hydrochloride (KP) ----- 100mg
(Western Department) Sarpogrelate hydrochloride (KP) ----- 200mg

- Additives: Microcrystalline cellulose, citric acid hydrate, Opadry white (OY-C-7000A), erythritol, calcium carboxymethyl cellulose, colloidal silicon oxide, collidone SR, hydroxypropyl cellulose, hypromellose

2. Effectiveness
Improvement of ischemic symptoms such as ulcers, pain, and cold sensation caused by chronic arterial occlusion (Buerger's disease, obstructive arteriosclerosis, diabetic peripheral angiopathy, etc.)

3. Dosage and dosage
Adults: 300 mg of sarpogrelate hydrochloride extended-release tablet is administered orally once a day after a meal. This medicine should be taken as is without chewing or crushing it.

4. Precautions for use
1. Do not administer to the following patients:
1) Patients with bleeding (hemophilia, capillary weakness, digestive tract ulcer, urinary tract bleeding, hemoptysis, vitreous hemorrhage, etc.) (There is a possibility of increased bleeding.)
2) Pregnant women or women who may be pregnant (refer to the section on administration to pregnant women and lactating women)

2. Administer with caution to the following patients:
1) Patients during menstruation (there is a risk of increased bleeding)
2) Patients with bleeding tendency or such predisposition (there is a risk of intensifying the bleeding tendency)
3) Patients taking anticoagulants (warfarin, etc.) or drugs that inhibit platelet aggregation (aspirin, ticlopidine, cilostazol, etc.) (there is a risk of increasing the bleeding tendency).
4) Patients with severe renal impairment (there is concern that excretion may be affected)
5) Elderly people

3. Adverse reactions
○ Sarpogrelate sustained-release tablets
1) In a clinical trial in which 74 of 149 patients with chronic arterial occlusion were administered this drug, a sustained-release tablet, and 75 were administered regular tablets, adverse reactions were reported in 31.1% of patients administered this drug and 40.0% of patients administered regular tablets. Among the adverse reactions that occurred in the group receiving this drug (74 people), there was one case of urticaria related to this drug, which was mild. Regardless of whether there is a causal relationship with this drug, the adverse reactions that occurred at least once are as follows.

- Infectious diseases: nasopharyngitis, conjunctivitis, upper respiratory tract infection
- Gastrointestinal system: indigestion, constipation, diarrhea, gastritis, gastrointestinal dysfunction
- Metabolism and nutrition: low blood sugar, decreased appetite
- Musculoskeletal system: back pain, muscle weakness
- Nervous system: headache, paresthesia
- Respiratory system: Coughing
- Skin and subcutaneous tissue: urticaria
- Vascular system: Blood pressure fluctuations
- Cardiovascular system: Atrial fibrillation
- Mental system: Anxiety
- Kidney and urinary system: Difficulty urinating
- Test value: increased blood pressure
- General abnormalities: chills, hot flashes, fever, wounds
2) Domestic post-marketing survey results
① As a result of a post-marketing survey conducted on 3,504 patients with chronic arterial occlusion over 4 years for re-examination in Korea, the incidence of adverse events was reported to be 6.74% (236/3,504 patients, 327 cases in total) regardless of causal relationship. Among these, serious adverse events unrelated to a causal relationship and serious adverse drug reactions for which a causal relationship cannot be ruled out are listed in the table below according to the frequency of occurrence.
※ Table: Refer to attached document
In addition, unexpected adverse events unrelated to causal relationships and unexpected adverse drug reactions for which causal relationships cannot be ruled out are listed in the following table according to the frequency of occurrence.
※ Table: Refer to attached document
② As a result of a post-marketing survey conducted on 152 patients with chronic arterial occlusion over a period of one year for re-examination in Korea, the occurrence of adverse events was reported to be 2.63% (4/152 patients, 4 cases in total) regardless of causal relationship. Among these, no serious or unexpected adverse events unrelated to causal relationships were reported.
The information specified below is based on data collected from clinical trials and post-marketing experience with Sarpogrelate Hydrochloride Generic Tablets.

○ Information collected from general tablets
The frequency of adverse reactions was sometimes classified as 0.1% or more to less than 5%, and rarely less than 0.1%.
1) Serious adverse reactions
(1) Bleeding tendency: Occasionally, bleeding such as gastrointestinal bleeding (e.g., hematemesis, bleeding, etc.), cerebral hemorrhage, and subcutaneous hemorrhage may occur, so observe thoroughly and take appropriate measures, such as discontinuing administration, if such symptoms appear.
(2) Blood disorders: Agranulocytosis, sometimes anemia, rarely platelet reduction, white blood cell reduction, etc. may occur, so observe thoroughly, and if adverse reactions occur, discontinue administration and take appropriate measures.
(3) Acute hepatitis, liver failure, or jaundice: Occasionally, liver dysfunction and jaundice accompanied by elevations of bilirubin, AST, ALT, ALP, γ-GTP, and LDH may occur, so observe thoroughly and take appropriate measures, such as discontinuing administration if these symptoms appear.
2) Other adverse reactions
(1) Hypersensitivity reaction: Erythema, urticaria, sometimes rash, redness, and rarely papules and itching may occur. If these symptoms appear, discontinue administration.
(2) Digestive system: Vomiting, stomatitis, sometimes nausea, foreign body sensation (esophagus), heartburn, abdominal pain, constipation, and rarely, loss of appetite, abdominal bloating, and diarrhea may occur.
(3) Circulatory system: Occasionally, palpitations, shortness of breath, chest pain, facial flushing, and swelling of the hands may occur.
(4) Mental nervous system: Drowsiness, loss of taste, headache, and rarely dizziness may occur.
(5) Kidney: Sometimes proteinuria, urinary occult blood, elevated BUN, and elevated creatinine may occur.
(6) Others: pharyngeal pain, pharyngeal discomfort, pharyngeal burning, sometimes weight gain, increased serum triglycerides, increased serum cholesterol, decreased serum albumin, decreased serum calcium, urinary sugar, urinary sediment, rarely edema, malaise, paralysis, fever, fatigue, etc. may occur.
3) As a result of a post-marketing survey conducted on 626 people over 6 years for re-examination in Korea, heartburn, diarrhea, headache, digestive tract bleeding, epistaxis, increased AST and ALT, increased bilirubin, increased cholesterol, and increased triglyceride were reported in 11 cases.

4. Generalism
It is advisable to have regular blood tests while taking this medicine.

5. Interaction
Caution should be exercised when co-administered with anticoagulants (warfarin, etc.) or drugs that inhibit platelet aggregation (aspirin, ticlopidine, cilostazol) as it may promote bleeding.

6. Administration to pregnant and lactating women
1) In animal experiments (rats), increased fetal mortality and decreased neonatal survival rates have been reported, so do not administer to pregnant women or women who may be pregnant.
2) Since secretion into milk was reported in animal experiments (rats), it is recommended not to administer to lactating women, but if administration is unavoidable, avoid breastfeeding.

7. Administration to children
Safety for children has not been established (there is no experience with use).

8. Storage and handling precautions
1) Keep out of reach of children.
2) Be careful because changing it into another container may cause an accident or is undesirable in terms of maintaining quality.


9. Pharmaceutical equivalence test information
A. fasting test

In a 2 × 2 crossover study, healthy adults received a single oral dose of one tablet each of the test product, Anplup 300 mg extended-release tablets (Shinil Pharmaceutical Co., Ltd.), and the reference product, Sapodifil SR 300 mg tablets (Alvogen Korea), under fasting conditions. Plasma sarpogrelate concentrations were measured in 54 participants. Statistical analysis of log-transformed AUCt and Cmax values showed that the 90% confidence intervals for the differences in means were within log 0.8 to log 1.25, demonstrating bioequivalence.
※ Table: Refer to attached document
B. Postprandial test
In a 2 × 2 crossover study, healthy adults received a single oral dose of one tablet each of the test product, Anplup 300 mg extended-release tablets (Shinil Pharmaceutical Co., Ltd.), and the reference product, Sapodifil SR 300 mg tablets (Alvogen Korea), after a meal. Plasma sarpogrelate concentrations were measured in 46 participants. Statistical analysis of log-transformed AUCt and Cmax values showed that the 90% confidence intervals for the differences in means were within log 0.8 to log 1.25, demonstrating bioequivalence.
※ Table: Refer to attached document

※ This drug was manufactured by Shinil Pharmaceutical Co., Ltd. and the entire process was contracted to Shinil Pharmaceutical Co., Ltd. using the same raw materials as Anple Up Extended-Release Tablet 300 mg (sarpogrelate hydrochloride) and using the same manufacturing method.

5. How to save
Airtight container, stored at room temperature (1~30℃)

6. Packaging unit
30 tablets/bottle, 100 tablets/bottle

7. Period of use
36 months from date of manufacture